Clark Estates Inc. NY Decreases Stake in Bristol-Myers Squibb (NYSE:BMY)

Clark Estates Inc. NY lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 10.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 47,650 shares of the biopharmaceutical company’s stock after selling 5,750 shares during the quarter. Clark Estates Inc. NY’s holdings in Bristol-Myers Squibb were worth $2,695,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of BMY. Souders Financial Advisors grew its stake in Bristol-Myers Squibb by 9.6% in the 4th quarter. Souders Financial Advisors now owns 6,362 shares of the biopharmaceutical company’s stock valued at $360,000 after purchasing an additional 558 shares during the period. Wealth Advisory Solutions LLC increased its holdings in Bristol-Myers Squibb by 4.4% during the fourth quarter. Wealth Advisory Solutions LLC now owns 6,708 shares of the biopharmaceutical company’s stock worth $379,000 after buying an additional 284 shares during the last quarter. Exencial Wealth Advisors LLC raised its position in Bristol-Myers Squibb by 8.8% in the fourth quarter. Exencial Wealth Advisors LLC now owns 16,776 shares of the biopharmaceutical company’s stock worth $949,000 after acquiring an additional 1,353 shares during the period. Commerzbank Aktiengesellschaft FI boosted its stake in Bristol-Myers Squibb by 36.8% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 13,526 shares of the biopharmaceutical company’s stock valued at $759,000 after acquiring an additional 3,639 shares during the last quarter. Finally, Tacita Capital Inc purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $39,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of Bristol-Myers Squibb stock in a transaction on Friday, February 14th. The shares were acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.09% of the stock is currently owned by insiders.

Analyst Ratings Changes

BMY has been the topic of several research analyst reports. Truist Financial upped their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets increased their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Cantor Fitzgerald upped their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $59.52 on Wednesday. The stock has a market cap of $120.77 billion, a P/E ratio of -13.46, a PEG ratio of 2.07 and a beta of 0.45. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The business’s 50-day moving average price is $57.23 and its two-hundred day moving average price is $54.93. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, equities analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.17%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.